Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer FSME-IMMUN / TicoVac by Year
FSME-IMMUN / TicoVac (tick-borne encephalitis vaccine) — U.S. reported YoY (%) (%)
Pfizer FSME-IMMUN / TicoVac: 13.0% in FY2025, up 1.0 pts from a year earlier.
Latest, FY2025
13.0%
Period ended Dec 31, 2025
Change on a year earlier
+1.0 pts
12.0% in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| FSME-IMMUN/TicoVac | 319 | 280 | 14% | 10% | 3 | 3 | 13% | 316 | 277 | 14% | 10%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | FSME-IMMUN / TicoVac (tick-borne encephalitis vaccine) — U.S. reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 13.0% | +1.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 12.0% | -14.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 26.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
Cite this data
StockData. (2026). Pfizer FSME-IMMUN / TicoVac (%), annual FY2023–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/fsme-yoy-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.